Plasma Aβ42/40 Ratio Detects Early Stages of Alzheimer’s Disease and Correlates with CSF and Neuroimaging Biomarkers in the AB255 Study - 21/11/24
, L. Sarasa 1, I. Monleón 1, I. San-José 1, J. Arbizu 2, P. Martínez-Lage 3, J. Munuera 4, A. Ruiz 5, L. Tárraga 5, M. Boada 5, M. Sarasa 1, 6The AB255 Study Group
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Abstract |
Background |
Easily accessible biomarkers are needed for the early identification of individuals at risk of developing Alzheimer’s disease (AD) in large population screening strategies.
Objectives |
This study evaluated the potential of plasma β-amyloid (Aβ) biomarkers in identifying early stages of AD and predicting cognitive decline over the following two years.
Design |
Total plasma Aβ42/40 ratio (TP42/40) was determined in 83 cognitively normal individuals (CN) and 145 subjects with amnestic mild cognitive impairment (a-MCI) stratified by an FDG-PET AD-risk pattern.
Results |
Significant lower TP42/40 ratio was found in a-MCI patients compared to CN. Moreover, a-MCIs with a highrisk FDG-PET pattern for AD showed even lower plasma ratio levels. Low TP42/40 at baseline increased the risk of progression to dementia by 70%. Furthermore, TP42/40 was inversely associated with neocortical amyloid deposition (measured with PiB-PET) and was concordant with the AD biomarker profile in cerebrospinal fluid (CSF).
Conclusions |
TP42/40 demonstrated value in the identification of individuals suffering a-MCI, in the prediction of progression to dementia, and in the detection of underlying AD pathology revealed by FDG-PET, Amyloid-PET and CSF biomarkers, being, thus, consistently associated with all the well-established indicators of AD.
Le texte complet de cet article est disponible en PDF.Key words : β-amyloid (Aβ), Alzheimer’s disease, plasma, biomarker, Aβ ratio
Plan
Vol 6 - N° 1
P. 34-41 - janvier 2019 Retour au numéro
Article précédent
- Pimavanserin in Alzheimer’s Disease Psychosis: Efficacy in Patients with More Pronounced Psychotic Symptoms
- Clive Ballard, J.M. Youakim, B. Coate, S. Stankovic
- Treatable Vascular Risk and Cognitive Performance in Persons Aged 35 Years or Older: Longitudinal Study of Six Years
- Marlise E.A. van Eersel, H. Joosten, R.T. Gansevoort, J.P.J. Slaets, G.J. Izaks
Bienvenue sur EM-consulte, la référence des professionnels de santé.